Biosimilar insulin glargine added to treatment with oral antidiabetics
Authors:
Marek Macko
Authors‘ workplace:
DIABETOL, s. r. o., Prešov
Published in:
Diab Obez 2020; 20(40): 110-111
Category:
Case studies
Sources
- Martinka E, Uličiansky V, Mokáň M et al. Konsenzuálne terapeutické odporúčanie Slovenskej diabetologickej spoločnosti pre diabetes mellitus 2. typu (2018). Forum Diab 2018; 7(1): 47–68.
- Davies MJ, D‘Alessio DA, Fradkin J et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018; 41(12): 2669–2701. Dostupné z DOI: <https://doi.org/10.2337/dci18–0033>.
- Tieu C, Lucas EJ, DePaola M et al. Efficacy and safety of biosimilar insulins compared to their reference products: A systematic review. PLoS One 2018; 13(4): e0195012. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0195012>.
Labels
Diabetology ObesitologyArticle was published in
Diabetes and obesity
2020 Issue 40
Most read in this issue
- Presence of alcohol in the breath of a diabetic patient – a possible forensic problem
- Metformin treatment is still under discussion
- Impaired awareness of hypoglycaemia: management and experience from Sheffield
- GDF15: a new predictive biomarker for type 2 diabetes mellitus in clinical practice